{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:06:59Z","timestamp":1789873619333,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pregabalin (PGL) is prescribed for the treatment of neuropathic pain, epilepsy, and general anxiety disorder; however, studies have shown that PGL is being misused. It is generally accepted that those who misuse PGL use it in amounts significantly greater than the recommended therapeutic dose. In some instances, such high doses may be well tolerated, and in some instances, the same dose may cause death. Individual variation and postmortem (PM) changes make it extremely challenging for toxicologists to determine if a drug concentration found at PM was contributory to death or not. Unfortunately, meaningful PM data, which can help with interpreting PGL concentrations in femoral-vein blood, are rare. Only one recommendation was found where an author suggested that a PGL concentration of &amp;gt;25 \u00b5g\/mL in PM blood should be considered as significant; however, in this case series PGL was only screened for in specific cases. To aid interpretation of PGL concentrations, reference data from toxicological analysis conducted on femoral-vein blood only from all manners of death are needed to compile meaningful and unbiased concentration ranges. This study looked at PGL femoral-vein blood concentrations in PM cases from all manners of death over a 2-year period. As it is impossible to define a PM concentration that should be considered toxic\/fatal, this study aimed to provide a concentration cut-off where the PGL may be considered a \u2018normal\u2019 incidental finding (unlikely to be the cause of death) or a \u2018cause for concern\u2019 where it may have been taken in excess and caused or contributed to death. This study recommends that a PGL concentration of \u226520 \u00b5g\/mL in femoral-vein blood should be considered as significant and a \u2018cause for concern\u2019. Concentrations of \u226419 \u00b5g\/mL may be considered a \u2018normal\u2019 incidental finding in death, but tolerance and other drug findings need to be considered.<\/jats:p>","DOI":"10.1093\/jat\/bkaf005","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T07:51:06Z","timestamp":1738655466000},"page":"272-279","source":"Crossref","is-referenced-by-count":2,"title":["Pregabalin concentrations: establishing \u2018normal\u2019 and \u2018cause for concern\u2019 concentration ranges in postmortem blood"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-9313","authenticated-orcid":false,"given":"Limon Khatun","family":"Nahar","sequence":"first","affiliation":[{"name":"Imperial College London, Toxicology Unit, Charing Cross Campus , London W6 8RP,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Paterson","sequence":"additional","affiliation":[{"name":"Imperial College London, Toxicology Unit, Charing Cross Campus , London W6 8RP,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"2025041701470604000_R1","article-title":"British National Formulary - Pregabalin","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"2025041701470604000_R2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/ijcp.12791","article-title":"Pregabalin prescriptions in the United Kingdom: a drug utilisation study of The Health Improvement Network (THIN) primary care database","volume":"70","author":"Asomaning","year":"2016","journal-title":"Int J Clin Pract"},{"key":"2025041701470604000_R3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2025041701470604000_R4","first-page":"1686","volume-title":"Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt","year":"2014","edition":"10th"},{"key":"2025041701470604000_R5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bcp.12277","article-title":"Misuse of the \u03b3-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK","volume":"78","author":"Kapil","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2025041701470604000_R6","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"Grosshans","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"2025041701470604000_R7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000321079","article-title":"Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data","volume":"80","author":"Schifano","year":"2011","journal-title":"Psychother Psychosom"},{"key":"2025041701470604000_R8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2010.09091269","article-title":"Pregabalin abuse, dependence, and withdrawal: a case report","volume":"167","author":"Grosshans","year":"2010","journal-title":"Am J Psychiatry"},{"key":"2025041701470604000_R9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5336\/caserep.2024-103115","article-title":"Two cases with pregabalin abuse: relieving the pain","volume":"32","author":"Karabulut","year":"2024","journal-title":"Turkiye Klinikleri J Case Rep"},{"key":"2025041701470604000_R10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"2025041701470604000_R11","article-title":"The Pharmacological Effects of Diacetylmorphine (Heroin) after Diffusion Through the Blood-Brain Barrier","author":"Zovko"},{"key":"2025041701470604000_R12","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1111\/bcp.14348","article-title":"Pregabalin poisoning and rising recreational use: a retrospective observational series","volume":"86","author":"Isoardi","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2025041701470604000_R13","article-title":"Deaths Related to Drug Poisoning in England and Wales: 2023 Registrations","author":"Office of National Statistics (ONS)"},{"key":"2025041701470604000_R14","article-title":"Prescription Cost Analysis England 2018","author":"National Health Service (NHS) England"},{"key":"2025041701470604000_R15","article-title":"Prescription Cost Analysis\u2014England\u20142023-24","author":"Business Services Authority NHS"},{"key":"2025041701470604000_R16","article-title":"Pregabalin and Gabapentin to Be Controlled as Class C Drugs","author":"UK Home Office"},{"key":"2025041701470604000_R17","article-title":"Deaths Related to Drug Poisoning by Selected Substances, England and Wales (2023 Registrations)","author":"Office of National Statistics (ONS)"},{"key":"2025041701470604000_R18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jat\/bkz036","article-title":"Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study","volume":"43","author":"Nahar","year":"2019","journal-title":"J Anal Toxicol"},{"key":"2025041701470604000_R19","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1093\/jat\/bkac090","article-title":"Reclassification of pregabalin in the UK: has it made a difference in deaths?","volume":"47","author":"Nahar","year":"2023","journal-title":"J Anal Toxicol"},{"key":"2025041701470604000_R20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ajem.2024.08.033","article-title":"Gabapentinoid prescribing patterns and predictors utilizing neural networks: an analysis across emergency departments Nationwide between 2012 and 2021","volume":"85","author":"Ramdin","year":"2024","journal-title":"Am J Emergency Med"},{"key":"2025041701470604000_R21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13181-010-0052-3","article-title":"Significant pregabalin toxicity managed with supportive care alone","volume":"6","author":"Wood","year":"2010","journal-title":"J Med Toxicol"},{"key":"2025041701470604000_R22","first-page":"162","article-title":"A case of pregabalin intoxication","volume":"23","author":"Miljevic","year":"2012","journal-title":"Psychiatrike= Psychiatriki"},{"key":"2025041701470604000_R23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/24734306.2018.1458465","article-title":"Pregabalin and paradoxical reaction of seizures in a large overdose","volume":"2","author":"Slocum","year":"2018","journal-title":"Toxicol Commun"},{"key":"2025041701470604000_R24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","article-title":"Profiles of pregabalin and gabapentin abuse by postmortem toxicology","volume":"241","author":"H\u00e4kkinen","year":"2014","journal-title":"Forensic Sci Int"},{"key":"2025041701470604000_R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.110830","article-title":"Pregabalin and gabapentin in non-opioid poisoning deaths","volume":"324","author":"Kriikku","year":"2021","journal-title":"Forensic Sci Int"},{"key":"2025041701470604000_R26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/ftd.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Therapeutic Drug Monitoring"},{"key":"2025041701470604000_R27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","article-title":"Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose\u2013response study in adults with partial seizures","volume":"45","author":"Arroyo","year":"2004","journal-title":"Epilepsia"},{"key":"2025041701470604000_R28","first-page":"339","article-title":"Abuse of pregabalin\u2014results of the postmortem toxicology from 2010 to 2012","volume":"80","author":"Lottner-Nau","year":"2013","journal-title":"Toxichem Krimtech"},{"key":"2025041701470604000_R29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.forsciint.2016.05.033","article-title":"Pregabalin concentrations in post-mortem blood\u2014a two year study","volume":"266","author":"Eastwood","year":"2016","journal-title":"Forensic Sci Int"},{"key":"2025041701470604000_R30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/1556-4029.13263","article-title":"Determining the toxicological significance of pregabalin in fatalities","volume":"62","author":"Elliott","year":"2017","journal-title":"J Forensic Sci"},{"key":"2025041701470604000_R31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1258\/rsmmsl.49.4.257","article-title":"Concentration distributions of the drugs most frequently identified in post-mortem femoral blood representing all causes of death","volume":"49","author":"Jones","year":"2009","journal-title":"Med Sci Law"},{"key":"2025041701470604000_R32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1520\/JFS14071J","article-title":"A compilation of fatal and control concentrations of drugs in postmortem femoral blood","volume":"42","author":"Druid","year":"1997","journal-title":"J Forensic Sci"},{"key":"2025041701470604000_R33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.scijus.2010.09.005","article-title":"The United Kingdom and Ireland Association of Forensic Toxicologists: forensic toxicology laboratory guidelines (2010)","volume":"50","author":"Cooper","year":"2010","journal-title":"Sci Justice"},{"key":"2025041701470604000_R34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jat\/bkx019","article-title":"Validated method for the screening and quantification of baclofen, gabapentin and pregabalin in human post-mortem whole blood using protein precipitation and liquid chromatography\u2013tandem mass spectrometry","volume":"41","author":"Nahar","year":"2017","journal-title":"J Anal Toxicol"},{"key":"2025041701470604000_R35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jat\/bku004","article-title":"Quantification of pregabalin using hydrophilic interaction HPLC-high-resolution MS in postmortem human samples: eighteen case reports","volume":"38","author":"Priez-Barallon","year":"2014","journal-title":"J Anal Toxicol"},{"key":"2025041701470604000_R36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.forsciint.2014.06.030","article-title":"Pregabalin serum levels in apprehended drivers","volume":"243","author":"Kriikku","year":"2014","journal-title":"Forensic Sci Int"},{"key":"2025041701470604000_R37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.7326\/M18-1136","article-title":"Pregabalin and the risk for opioid-related death: a nested case\u2013control study","volume":"169","author":"Gomes","year":"2018","journal-title":"Ann Internal Med"},{"key":"2025041701470604000_R38","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/dta.2655","article-title":"Summary statistics for drug concentrations in post-mortem femoral blood representing all causes of death","volume":"11","author":"Ketola","year":"2019","journal-title":"Drug Test Anal"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaf005\/61745909\/bkaf005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/49\/4\/272\/61745909\/bkaf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/49\/4\/272\/61745909\/bkaf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:47:40Z","timestamp":1744868860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/49\/4\/272\/7997913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,4]]},"published-print":{"date-parts":[[2025,4,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaf005","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,2,4]]}}}